Abstract Number: 186 • 2012 ACR/ARHP Annual Meeting
Long-Term Infliximab Therapy in Patients with Behcet’s Disease Is Well Tolerated without Increasing Risk of Serious Infections
Background/Purpose: Infliximab (IFX) is a monoclonal antibody against tumor necrosis factor-a (TNF-a) and is increasingly used in various immune-related diseases including rheumatoid arthritis (RA), ankylosing…Abstract Number: 147 • 2012 ACR/ARHP Annual Meeting
Improvements in Long-Term Health-Related Quality of Life in Chronic Gout Patients Refractory to Conventional Therapies Treated with Pegloticase: Results From Responder Cohort
Background/Purpose: In replicate, 6-month, randomized, placebo-controlled Phase 3 clinical trials a subgroup of patients with treatment-refractory chronic gout (RCG) who received pegloticase infusions (8 mg)…Abstract Number: 148 • 2012 ACR/ARHP Annual Meeting
Towards a Preliminary Definition of Remission From Gout
Background/Purpose: There is currently no agreed criterion for remission in chronic gout. The aim of this study was to develop a preliminary definition for remission…Abstract Number: 149 • 2012 ACR/ARHP Annual Meeting
Natural Language Processing in the Evaluation of Gout Quality Indicators
Background/Purpose: Gout is a common inflammatory arthritis with significant impact on both patients and health care systems. Despite ACR/EULAR management guidelines and gout quality indicators…Abstract Number: 150 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Long-Term Safety When Added to Allopurinol in the Chronic Management of Gout: A Phase 2 24-Week Blinded Safety Extension and Vaccine Challenge Study
Background/Purpose: A majority of gout patients treated with 300 mg/d allopurinol do not reach the therapeutic goal range serum uric acid concentration (sUA) of 4…Abstract Number: 151 • 2012 ACR/ARHP Annual Meeting
Management of Gout Attacks in the Community
Background/Purpose: We previously examined management of gout attacks in the community in 2003-4. Since then, new agents have become available and gout publications have increased,…Abstract Number: 152 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Reduction: Estimation of Number Needed to Treat to Benefit (NNTB)
Background/Purpose: Two similarly designed phase 3 randomized clinical trials (PRESURGE-1 and PRESURGE-2) in gout patients initiating urate-lowering therapy (ULT) showed that subcutaneous treatment with the…Abstract Number: 153 • 2012 ACR/ARHP Annual Meeting
Prevention of Recurrent Calcium Stones in Subjects with Hyperuricosuria: A Randomized Controlled Trial of Febuxostat Vs Allopurinol
Background/Purpose: About one-third of patients with recurrent calcium oxalate (CaOx) stones have hyperuricosuria as a urinary risk factor. Febuxostat (FEB), a newer xanthine oxidase inhibitor…Abstract Number: 154 • 2012 ACR/ARHP Annual Meeting
Dual-Energy Computed Tomography As a Diagnostic Tool for Gout During Intercritical Periods
Background/Purpose: Dual-energy computed tomography (DECT) is a sensitive method for identifying uric acid deposits in joints and periarticular soft tissues in patients suspected of having…Abstract Number: 155 • 2012 ACR/ARHP Annual Meeting
Accuracy of International Classification of Disease Codes for Calcium Pyrophosphate Disease in the Veterans Adminstration Healthcare System
Background/Purpose: Calcium pyrophosphate disease (CPPD) commonly affects elderly patients, but few advances in our management of this disease have occurred in the 50 years since…Abstract Number: 156 • 2012 ACR/ARHP Annual Meeting
Menopause and the Prevalence of Gout and Hyperuricemia: An Age-Matched Case Control Study
Background/Purpose: Among women, the prevalence of gouty arthritis (gout) and hyperuricemia (serum urate>6.0 mg/dL) increases steeply after the age 60. This increase has been attributed…Abstract Number: 157 • 2012 ACR/ARHP Annual Meeting
Prevalence of Gout Among Adults with Chronic Kidney Disease in the United States, 2009-10
Background/Purpose: The kidney is a major route of clearance of uric acid, a product of purine metabolism. The links between kidney disease, hyperuricemia, and gout…Abstract Number: 158 • 2012 ACR/ARHP Annual Meeting
Focus Groups Reveal Knowledge Gaps in Patients with Gout-A Qualitative Study
Background/Purpose: Gout is the most treatable arthritis in the Western World and there are effective medications available to treat both acute episodes and chronic gout.…Abstract Number: 159 • 2012 ACR/ARHP Annual Meeting
Clinical Efficacy Outcomes with up to 3 Years of Pegloticase Treatment for Refractory Chronic Gout
Background/Purpose: Pegloticase, a recombinant modified mammalian uricase conjugated to mPEG, was approved for use in refractory chronic gout in the US in 2010. The Phase…Abstract Number: 160 • 2012 ACR/ARHP Annual Meeting
Pegloticase Long-Term Safety: Data From the Open-Label Extension Trial
Background/Purpose: Pegloticase is a recombinant modified mammalian uricase conjugated to mPEG and approved for treatment of refractory chronic gout. Pegloticase safety was evaluated during 2…